Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Astronomers discover remarkable triple-star system just 28 light-years from Earth

Astronomers have discovered a stellar system just 28 light-years from Earth that challenges our understanding of how stars live, die and interact as they evolve.

Given the name Welopōʻai, this unusual triple-star system was discovered by an international team of scientists led by the Trottier Institute for Research on Exoplanets (IREx) at Université de Montréal.

They detail their discovery in a study published in Astronomy & Astrophysics.

Lifeboat Foundation Books

Read our 4 books at https://lifeboat.com/ex/books and visit our store at https://lifeboat.com/store.

Visit our site at https://lifeboat.com. Participate in our programs at https://lifeboat.com/ex/programs and read our reports at https://lifeboat.com/ex/reports. Follow our X feed at https://twitter.com/LifeboatHQ. Watch our YouTube channel at https://youtube.com/lifeboathq. Read our blog at https://lifeboat.com/blog. Join our LinkedIn group at https://www.linkedin.com/groups/35656. Subscribe to our newsletter at https://lifeboat.com/newsletter.cgi.

Interact with the author of “The Human Race to the Future: What Could Happen—and What to Do” at https://www.facebook.com/groups/thehumanracetothefuture.

The Lifeboat Foundation is a nonprofit nongovernmental organization dedicated to encouraging scientific advancements while helping humanity survive existential risks and possible misuse of increasingly powerful technologies, including genetic engineering, nanotechnology, and robotics/AI, as we move towards the Singularity.

Lifeboat Foundation is pursuing a variety of options, including helping to accelerate the development of technologies to defend humanity, such as new methods to combat viruses, effective nanotechnological defensive strategies, and even self-sustaining space colonies in case the other defensive strategies fail.

We believe that, in some situations, it might be feasible to relinquish technological capacity in the public interest (for example, we are against the U.S. government posting the recipe for the 1918 flu virus on the internet). We have some of the best minds on the planet working on programs to enable our survival. We invite you to join our cause!


A Flying Microrobot With a Built-In Brain

Weighing less than a paperclip, this bug-sized flyer carries its own onboard sensors and microcontroller to navigate complex trajectories all while handling perception and control in mid-air. (Learn more: https://news.mit.edu/2026/featherweig…

Watch more videos from MIT: https://www.youtube.com/user/MITNewsOf… The Massachusetts Institute of Technology is an independent, coeducational, privately endowed university in Cambridge, Massachusetts. Our mission is to advance knowledge; to educate students in science, engineering, technology, humanities and social sciences; and to tackle the most pressing problems facing the world today. We are a community of hands-on problem-solvers in love with fundamental science and eager to make the world a better place. The MIT YouTube channel features videos about all types of MIT research, including the robot cheetah, LIGO, gravitational waves, mathematics, and bombardier beetles, as well as videos on origami, time capsules, and other aspects of life and culture on the MIT campus. Our goal is to open the doors of MIT and bring the Institute to the world through video.

The Massachusetts Institute of Technology is an independent, coeducational, privately endowed university in Cambridge, Massachusetts. Our mission is to advance knowledge; to educate students in science, engineering, technology, humanities and social sciences; and to tackle the most pressing problems facing the world today. We are a community of hands-on problem-solvers in love with fundamental science and eager to make the world a better place.

Realizing the potential of agonistic antibody immunotherapy

Agonistic antibodies initiate signalling by the receptors they target, mimicking the activities of native ligands. This Review discusses the clinical successes and failures of agonistic antibodies and explains how recent mechanistic insights should broaden the scope and improve the safety and efficacy of immunotherapies based on these agents.